Prophase Labs (PRPH) Investor Presentation summary

Strategic initiatives and business verticals

• Pursuing over $50 million in net near-term cash recovery from COVID-19 receivables through a contingency-based legal initiative with Crown Medical Collections, targeting over 1,100 insurance companies and expecting meaningful settlements soon.

• BE-Smart esophageal cancer diagnostic test validated in a pivotal study, with full USPTO patent approval and a target market of $7–14 billion; commercialization efforts are underway, including collaborations with Mayo Clinic and key opinion leaders.

• Nebula Genomics, with a 16-petabyte DNA dataset from 130 countries, offers whole genome sequencing and bioinformatics, and is positioned as a valuable acquisition candidate in the genomics sector.

• Launched DNA Complete and DNA Expand, direct-to-consumer genomic products providing comprehensive health and ancestry reports, with a privacy-first approach and scalable subscription-based revenue model.

• Developing Equivir, a clinically studied dietary supplement, with plans for market introduction in early 2025.

Recent performance and operational milestones

• Sold Pharmaloz Manufacturing for $23.6 million and shut down the genomics laboratory, resulting in significant annual cost savings.

• Reduced headcount and IT overhead, completing a transition to a leaner company structure for H2 2025.

• Opened a world-class whole genome sequencing lab in 2023, enhancing capabilities and reducing costs.

• Announced full USPTO approval for a patent protecting esophageal adenocarcinoma risk assessment in Q3 2025.

• Initiated expansion and automation at Pharmaloz Manufacturing in 2024, increasing capacity and profitability prior to its sale.

BE-Smart esophageal cancer diagnostic: market and clinical validation

• Esophageal adenocarcinoma has a high mortality rate and rising incidence; early detection is critical for improving outcomes.

• BE-Smart test uses existing biopsy samples from routine endoscopies, offering higher sensitivity and specificity than liquid biopsies.

• Achieved over 95% technical success rate in validation studies, with dual capability to analyze both pinch and brush biopsies.

• Full USPTO patent granted and pivotal validation study published, confirming clinical utility as a risk stratification tool.

• Commercialization strategy includes cash-based launch, payer discussions, and potential partnerships with large pharma or cancer-testing companies.